Download PDF
Thromb Haemost 2016; 115(06): 1209-1219
DOI: 10.1160/TH15-11-0895
Stroke, Systemic or Venous Thromboembolism
Schattauer GmbH

Use of antipsychotics and risk of venous thromboembolism in postmenopausal women

A population-based nested case-control study
Meng-Ting Wang
1   School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
,
Jun-Ting Liou
2   Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
,
Yun-Wen Huang
1   School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
,
Chen Wei Lin
1   School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
,
Gwo-Jang Wu
3   Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, Republic of China
4   Department of Obstertrics and Gynecology, Reproductive Medical Center, Tri-Service General Hospital, Taipei, Taiwan, Republic of China
,
Che-Li Chu
1   School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
,
Chin-Bin Yeh
5   Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China
,
Yun-Han Wang
1   School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
› Author Affiliations Financial support: This study was supported by the National Science Council (NSC102–2320-B016–005).
Further Information

Publication History

Received: 21 November 2015

Accepted after major revision: 20 February 2016

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Summary

Despite continued uncertainty of venous thromboembolism (VTE) caused from antipsychotic agents, this safety issue has not been examined in postmenopausal women, a population with high usages of antipsychotics and at high risk for VTE. We assessed whether antipsychotic use was associated with an increased VTE risk in women after menopause. We conducted a nested case-control study of all Taiwanese women aged ≥ 50 years (n = 316,132) using a nationwide healthcare claims database between 2000 and 2011. All newly diagnosed VTE patients treated with an anticoagulant or thrombectomy surgery were identified as cases (n = 2,520) and individually matched to select controls (n = 24,223) by cohort entry date, age, cancer diagnosis and major surgery procedure. The odds ratios (ORs) and 95 % confidence interval (CI) of VTE associated with antipsychotics were estimated by multivariate conditional logistic regressions. Current use of antipsychotics was associated with a 1.90-fold (95 % CI = 1.64–2.19) increased VTE risk compared with nonuse in postmenopausal women. The VTE risk existed in a dose-dependent fashion (test for trend, p<0.001), with a more than quadrupled risk for high-dose antipsychotics (adjusted OR = 4.60; 95 % CI = 2.88–7.33). Current parenteral administration of antipsychotics also led to a 3.46-fold increased risk (95 % CI = 2.39–5.00). Conversely, there was no increased VTE risk when antipsychotics were discontinued for > 30 days. In conclusion, current use of antipsychotics is significantly associated with a dose-dependent increased risk of VTE in postmenopausal women, especially for those currently taking high-dose or receiving parenteral antipsychotics.

Keywords

Venous thromboembolism (VTE) - nested case-control - antipsychotics - postmenopause - epidemiology

 

  • References

  • 1 Tagalakis V, Patenaude V, Kahn SR. et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med 2013; 126 832 e13-21.
    PubMedGoogle Scholar
  • 2 Lefebvre P, Laliberte F, Nutescu EA. et al. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm 2012; 18: 363-374.
    PubMedGoogle Scholar
  • 3 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-30.
    PubMedGoogle Scholar
  • 4 Allenet B, Schmidlin S, Genty C. et al. Antipsychotic drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf 2012; 21: 42-48.
    CrossrefPubMedGoogle Scholar
  • 5 Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf 2014; 37: 79-90.
    CrossrefPubMedGoogle Scholar
  • 6 Lacut K, Le Gal G, Couturaud F. et al. Association between antipsychotic drugs, antidepressant drugs and venous thromboembolism: results from the EDITH case-control study. Fundam Clin Pharmacol 2007; 21: 643-650.
    CrossrefPubMedGoogle Scholar
  • 7 Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. Br Med J 2010; 341: c4245.
    CrossrefPubMedGoogle Scholar
  • 8 Parkin L, Skegg DC, Herbison GP. et al. Psychotropic drugs and fatal pulmonary embolism. Pharmacoepidemiol Drug Saf 2003; 12: 647-652.
    CrossrefPubMedGoogle Scholar
  • 9 Zhang R, Dong L, Shao F. et al. Antipsychotics and venous thromboembolism risk: a meta-analysis. Pharmacopsychiatry 2011; 44: 183-188.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Jonsson AK, Spigset O, Hagg S. Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management. CNS Drugs 2012; 26: 649-662.
    CrossrefPubMedGoogle Scholar
  • 11 Kleijer BC, Heerdink ER, Egberts TC. et al. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol 2010; 30: 526-530.
    CrossrefPubMedGoogle Scholar
  • 12 Ray JG, Mamdani MM, Yeo EL. Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism. Thromb Haemost 2002; 88: 205-209.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Schmedt N, Garbe E. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients with dementia. J Clin Psychopharmacol 2013; 33: 753-758.
    CrossrefPubMedGoogle Scholar
  • 14 Jonsson AK, Horvath-Puho E, Hagg S. et al. Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clin Epidemiol 2009; 01: 19-26.
    PubMedGoogle Scholar
  • 15 Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219-1223.
    CrossrefPubMedGoogle Scholar
  • 16 Wu CS, Lin CC, Chang CM. et al. Antipsychotic treatment and the occurrence of venous thromboembolism: a 10-year nationwide registry study. J Clin Psychiatry 2013; 74: 918-924.
    CrossrefPubMedGoogle Scholar
  • 17 Bucciarelli P, Mannucci PM. The hemostatic system through aging and menopause. Climacteric 2009; 12 (Suppl. 01) 47-51.
    CrossrefPubMedGoogle Scholar
  • 18 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
    CrossrefPubMedGoogle Scholar
  • 19 Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and meta-analysis. J Steroid Biochem Mol Biol 2014; 142: 90-98.
    CrossrefPubMedGoogle Scholar
  • 20 Falkenburg J, Tracy DK. Sex and schizophrenia: a review of gender differences. Psychosis 2014; 06: 61-69.
    CrossrefPubMedGoogle Scholar
  • 21 Chen YC, Yeh HY, Wu JC. et al. Taiwan’s National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics 2011; 86: 365-380.
    CrossrefPubMedGoogle Scholar
  • 22 Laws & Regulations Database of The Republic of China. National Health Insurance Medical Expense Declaration and Reimbursement, and Review of Medical Services. Available at http://law.moj.gov.tw/LawClass/LawCon- tent.aspx?PCODE=L0060006 Accessed January 28. 2016.
    PubMed
  • 23 Bureau of Health Promotion, Department of Health, R. O. C. (Taiwan). Available at: http://www.hpa.gov.tw/bhpnet/web/news/news.aspx?no=200712250210 Accessed on July 23, 2015.
    PubMed
  • 24 Lee CH, Cheng CL, Chang CH. et al. Universal pharmacological thromboprophylaxis for total knee arthroplasty may not be necessary in low-risk populations: a nationwide study in Taiwan. J Thromb Haemost 2012; 10: 56-63.
    CrossrefPubMedGoogle Scholar
  • 25 Felcher AH, Mularski RA, Mosen DM. et al. Incidence and risk factors for venous thromboembolic disease in podiatric surgery. Chest 2009; 135: 917-922.
    CrossrefPubMedGoogle Scholar
  • 26 Tamariz L, Harkins T, Nair V. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data. Pharmacoepidemiol Drug Saf 2012; (21) (Suppl. 01) 154-162.
    PubMedGoogle Scholar
  • 27 Sultan AA, West J, Tata LJ. et al. Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study. Br J Haematol 2012; 156: 366-373.
    CrossrefPubMedGoogle Scholar
  • 28 Pakzad-Vaezi KL, Etminan M, Mikelberg FS. The association between cataract surgery and atypical antipsychotic use: a nested case-control study. Am J Ophthalmol 2013; 156: 1141-1146. e1.
    CrossrefPubMedGoogle Scholar
  • 29 Chang CM, Wu KY, Liang HY. et al. Adherence patterns with first-versus second-generation antipsychotics for newly diagnosed schizophrenia in Taiwan. Psychiatr Serv 2012; 63: 504-507.
    CrossrefPubMedGoogle Scholar
  • 30 Gardner DM, Murphy AL, O’Donnell H. et al. International consensus study of antipsychotic dosing. Am J Psychiatry 2010; 167: 686-693.
    CrossrefPubMedGoogle Scholar
  • 31 Orr MW, Knox JM, Allen R. et al. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol 1981; 11: 255-259.
    CrossrefPubMedGoogle Scholar
  • 32 Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol 1991; 32: 677-684.
    PubMedGoogle Scholar
  • 33 Kroeze WK, Hufeisen SJ, Popadak BA. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519-526.
    CrossrefPubMedGoogle Scholar
  • 34 Roth BL, Lopez E, Beischel S. et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 2004; 102: 99-110.
    CrossrefPubMedGoogle Scholar
  • 35 Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res 2011; 46: 399-424.
    CrossrefPubMedGoogle Scholar
  • 36 Tadrous M, Gagne JJ, Sturmer T. et al. Disease risk score as a confounder summary method: systematic review and recommendations. Pharmacoepidemiol Drug Saf 2013; 22: 122-129.
    CrossrefPubMedGoogle Scholar
  • 37 Bjerre LM, LeLorier J. Expressing the magnitude of adverse effects in case-control studies: “the number of patients needed to be treated for one additional patient to be harmed”. Br Med J 2000; 320: 503-506.
    CrossrefPubMedGoogle Scholar
  • 38 Masopust J, Maly R, Andrys C. et al. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011; 11: 2.
    CrossrefPubMedGoogle Scholar
  • 39 Hsu WY, Lane HY, Lin CL. et al. A population-based cohort study on deep vein thrombosis and pulmonary embolism among schizophrenia patients. Schizophr Res 2015; 162: 248-252.
    CrossrefPubMedGoogle Scholar
  • 40 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
    CrossrefPubMedGoogle Scholar
  • 41 Lee CH, Cheng CL, Lin LJ. et al. Epidemiology and predictors of short-term mortality in symptomatic venous thromboembolism. Circ J 2011; 75: 1998-2004.
    CrossrefPubMedGoogle Scholar
  • 42 Lee CH, Lin LJ, Cheng CL. et al. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010; 08: 1515-1523.
    CrossrefPubMedGoogle Scholar
  • 43 Ishiguro C, Wang X, Li L. et al. Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD. Pharmacoepidemiol Drug Saf 2014; 23: 1168-1175.
    CrossrefPubMedGoogle Scholar
  • 44 Bressolle F, Bres J, Faure-Jeantis A. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. J Pharm Sci 1992; 81: 26-32.
    CrossrefPubMedGoogle Scholar
  • 45 Chang WH, Lam YW, Jann MW. et al. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology 1992; 106: 517-522.
    CrossrefPubMedGoogle Scholar
  • 46 Liperoti R, Pedone C, Lapane KL. et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165: 2677-2682.
    CrossrefPubMedGoogle Scholar
  • 47 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000; 83: 657-660.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Buesing KL, Mullapudi B, Flowers KA. Deep venous thrombosis and venous thromboembolism prophylaxis. Surg Clin North Am 2015; 95: 285-300.
    CrossrefPubMedGoogle Scholar
  • 49 Gould MK, Garcia DA, Wren SM. et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e227S-77S.
    CrossrefPubMedGoogle Scholar
  • 50 Nunez MJ, Villalba JC, Cebrian E. et al. Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry. Thromb Res 2012; 130: 173-177.
    CrossrefPubMedGoogle Scholar